ZW427 / Zymeworks - LARVOL DELTA

ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers (AACR 2026) - "The pan-RASi ADC platform that has been developed shows encouraging tolerability in mice and an imminent toxicology study of ZW427 in non-human primates will further define its safety profile. Overall, the data supports the potential of ZW427 as a novel, highly differentiated therapeutic agent against Ly6E-expressing RAS mutant cancer indications."

ADC • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • LY6E